ID   RN125_HUMAN             Reviewed;         232 AA.
AC   Q96EQ8; Q9NX39;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 4.
DT   10-MAY-2017, entry version 138.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF125 {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000269|PubMed:15843525, ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375};
DE   AltName: Full=RING finger protein 125 {ECO:0000312|HGNC:HGNC:21150};
DE   AltName: Full=T-cell RING activation protein 1 {ECO:0000303|PubMed:12974981};
DE            Short=TRAC-1 {ECO:0000303|PubMed:12974981};
GN   Name=RNF125 {ECO:0000312|HGNC:HGNC:21150};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION, AND TISSUE SPECIFICITY.
RX   PubMed=12974981; DOI=10.1186/1475-4924-2-21;
RA   Chu P., Pardo J., Zhao H., Li C.C., Pali E., Shen M.M., Qu K.,
RA   Yu S.X., Huang B.C.B., Yu P., Masuda E.S., Molineaux S.M.,
RA   Kolbinger F., Aversa G., de Vries J., Payan D.G., Liao X.C.;
RT   "Systematic identification of regulatory proteins critical for T-cell
RT   activation.";
RL   J. Biol. 2:21.1-21.16(2003).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   GLY-2; CYS-37; CYS-40; HIS-54; CYS-57; CYS-72 AND CYS-75.
RX   PubMed=15843525; DOI=10.4049/jimmunol.174.9.5288;
RA   Zhao H., Li C.C., Pardo J., Chu P.C., Liao C.X., Huang J., Dong J.G.,
RA   Zhou X., Huang Q., Huang B.C.B., Bennett M.K., Molineaux S.M., Lu H.,
RA   Daniel-Issakani S., Payan D.G., Masuda E.S.;
RT   "A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell
RT   activation.";
RL   J. Immunol. 174:5288-5297(2005).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-72 AND CYS-75.
RX   PubMed=17460044; DOI=10.1073/pnas.0611551104;
RA   Arimoto K., Takahashi H., Hishiki T., Konishi H., Fujita T.,
RA   Shimotohno K.;
RT   "Negative regulation of the RIG-I signaling by the ubiquitin ligase
RT   RNF125.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7500-7505(2007).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF CYS-37 AND CYS-40.
RX   PubMed=17643463; DOI=10.1016/j.virol.2007.06.028;
RA   Shoji-Kawata S., Zhong Q., Kameoka M., Iwabu Y., Sapsutthipas S.,
RA   Luftig R.B., Ikuta K.;
RT   "The RING finger ubiquitin ligase RNF125/TRAC-1 down-modulates HIV-1
RT   replication in primary human peripheral blood mononuclear cells.";
RL   Virology 368:191-204(2007).
RN   [7]
RP   SUBCELLULAR LOCATION, AUTOUBIQUITINATION, MYRISTOYLATION AT GLY-2, AND
RP   MUTAGENESIS OF GLY-2; CYS-37; CYS-40; VAL-217 AND SER-221.
RX   PubMed=17990982; DOI=10.1042/BJ20070995;
RA   Giannini A.L., Gao Y., Bijlmakers M.J.;
RT   "T-cell regulator RNF125/TRAC-1 belongs to a novel family of ubiquitin
RT   ligases with zinc fingers and a ubiquitin-binding domain.";
RL   Biochem. J. 410:101-111(2008).
RN   [8]
RP   INVOLVEMENT IN TNORS, AND VARIANTS TNORS ILE-112; LEU-163 AND CYS-174.
RX   PubMed=25196541; DOI=10.1002/humu.22689;
RG   SOGRI Consortium;
RA   Tenorio J., Mansilla A., Valencia M., Martinez-Glez V., Romanelli V.,
RA   Arias P., Castrejon N., Poletta F., Guillen-Navarro E., Gordo G.,
RA   Mansilla E., Garcia-Santiago F., Gonzalez-Casado I., Vallespin E.,
RA   Palomares M., Mori M.A., Santos-Simarro F., Garcia-Minaur S.,
RA   Fernandez L., Mena R., Benito-Sanz S., del Pozo A., Silla J.C.,
RA   Ibanez K., Lopez-Granados E., Martin-Trujillo A., Montaner D.,
RA   Heath K.E., Campos-Barros A., Dopazo J., Nevado J., Monk D.,
RA   Ruiz-Perez V.L., Lapunzina P.;
RT   "A new overgrowth syndrome is due to mutations in RNF125.";
RL   Hum. Mutat. 35:1436-1441(2014).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-72 AND CYS-75.
RX   PubMed=25591766; DOI=10.1159/000369691;
RA   Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.;
RT   "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.";
RL   Cell. Physiol. Biochem. 35:237-245(2015).
RN   [10]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=26027934; DOI=10.1016/j.celrep.2015.04.049;
RA   Kim H., Frederick D.T., Levesque M.P., Cooper Z.A., Feng Y.,
RA   Krepler C., Brill L., Samuels Y., Hayward N.K., Perlina A., Piris A.,
RA   Zhang T., Halaban R., Herlyn M.M., Brown K.M., Wargo J.A., Dummer R.,
RA   Flaherty K.T., Ronai Z.A.;
RT   "Downregulation of the ubiquitin ligase RNF125 underlies resistance of
RT   melanoma cells to BRAF inhibitors via JAK1 deregulation.";
RL   Cell Rep. 11:1458-1473(2015).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH VCP.
RX   PubMed=26471729; DOI=10.15252/embj.201591888;
RA   Hao Q., Jiao S., Shi Z., Li C., Meng X., Zhang Z., Wang Y., Song X.,
RA   Wang W., Zhang R., Zhao Y., Wong C.C., Zhou Z.;
RT   "A non-canonical role of the p97 complex in RIG-I antiviral
RT   signaling.";
RL   EMBO J. 34:2903-2920(2015).
RN   [12]
RP   INDUCTION.
RX   PubMed=26202983; DOI=10.4049/jimmunol.1500370;
RA   Zhu B., Ye J., Nie Y., Ashraf U., Zohaib A., Duan X., Fu Z.F.,
RA   Song Y., Chen H., Cao S.;
RT   "MicroRNA-15b Modulates Japanese Encephalitis Virus-Mediated
RT   Inflammation via Targeting RNF125.";
RL   J. Immunol. 195:2251-2262(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEX WITH ZINC, FUNCTION,
RP   CATALYTIC ACTIVITY, INTERACTION WITH UBE2D1, DOMAIN, AND MUTAGENESIS
RP   OF 100-CYS--CYS-103 AND 109-LEU--ARG-113.
RX   PubMed=27411375; DOI=10.1038/srep29232;
RA   Bijlmakers M.J., Teixeira J.M., Boer R., Mayzel M., Puig-Sarries P.,
RA   Karlsson G., Coll M., Pons M., Crosas B.;
RT   "A C2HC zinc finger is essential for the RING-E2 interaction of the
RT   ubiquitin ligase RNF125.";
RL   Sci. Rep. 6:29232-29232(2016).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       and subsequent proteasomal degradation of target proteins, such as
CC       DDX58/RIG-I, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53
CC       (PubMed:15843525, PubMed:17460044, PubMed:17643463,
CC       PubMed:26027934, PubMed:26471729, PubMed:25591766,
CC       PubMed:27411375). Acts as a negative regulator of type I
CC       interferon production by mediating ubiquitination of DDX58/RIG-I
CC       at 'Lys-181', leading to DDX58/RIG-I degradation (PubMed:17460044,
CC       PubMed:26471729). Mediates ubiquitination and subsequent
CC       degradation of p53/TP53 (PubMed:25591766). Mediates ubiquitination
CC       and subsequent degradation of JAK1 (PubMed:26027934). Acts as a
CC       positive regulator of T-cell activation (PubMed:15843525).
CC       {ECO:0000269|PubMed:15843525, ECO:0000269|PubMed:17460044,
CC       ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:25591766,
CC       ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26471729,
CC       ECO:0000269|PubMed:27411375}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:15843525,
CC       ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:17643463,
CC       ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:26027934,
CC       ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:15843525, ECO:0000269|PubMed:17460044,
CC       ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:25591766,
CC       ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26471729,
CC       ECO:0000269|PubMed:27411375}.
CC   -!- SUBUNIT: Interacts with UBE2D1 (PubMed:27411375). Interacts with
CC       VCP/p97; leading to recruit RNF125 to DDX58/RIG-I and promote
CC       ubiquitination of DDX58/RIG-I (PubMed:26471729).
CC       {ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:17990982}; Lipid-anchor
CC       {ECO:0000269|PubMed:17990982}. Note=Shows a reticular staining
CC       pattern within the cell and is probably expressed at other
CC       intracellular membranes in addition to the Golgi membrane. Not
CC       detected at the plasma membrane. {ECO:0000269|PubMed:17990982}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in lymphoid tissues,
CC       including bone marrow, spleen and thymus. Also weakly expressed in
CC       other tissues. Predominant in the CD4(+) and CD8(+) T-cells,
CC       suggesting that it is preferentially confined to T-cells.
CC       {ECO:0000269|PubMed:12974981, ECO:0000269|PubMed:15843525}.
CC   -!- INDUCTION: Down-regulated by miR-15b (PubMed:26202983). Down-
CC       regulated in BRAFi resistant melanomas, leading to increased
CC       levels of JAK1 and possibly promoting BRAFi resistance.
CC       {ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26202983}.
CC   -!- DOMAIN: The C2HC RNF-type zinc finger and the linker region
CC       stabilize the RING-type zinc finger, leading to promote binding of
CC       the RING-type zinc finger to the ubiquitin-conjugating enzyme E2
CC       (donor ubiquitin) (PubMed:27411375).
CC       {ECO:0000269|PubMed:27411375}.
CC   -!- PTM: Autoubiquitinated, leading to its subsequent proteasomal
CC       degradation. {ECO:0000269|PubMed:17990982}.
CC   -!- DISEASE: Tenorio syndrome (TNORS) [MIM:616260]: A disease
CC       characterized by overgrowth, macrocephaly, and intellectual
CC       disability. Some patients may have mild hydrocephaly,
CC       hypoglycemia, and inflammatory diseases resembling Sjogren
CC       syndrome. {ECO:0000269|PubMed:25196541}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK000463; BAA91182.1; -; mRNA.
DR   EMBL; BC012021; AAH12021.1; -; mRNA.
DR   CCDS; CCDS11902.1; -.
DR   RefSeq; NP_060301.2; NM_017831.3.
DR   UniGene; Hs.633703; -.
DR   PDB; 5DKA; X-ray; 1.55 A; A/B=1-232.
DR   PDBsum; 5DKA; -.
DR   ProteinModelPortal; Q96EQ8; -.
DR   SMR; Q96EQ8; -.
DR   BioGrid; 120281; 20.
DR   DIP; DIP-52778N; -.
DR   IntAct; Q96EQ8; 19.
DR   STRING; 9606.ENSP00000217740; -.
DR   iPTMnet; Q96EQ8; -.
DR   PhosphoSitePlus; Q96EQ8; -.
DR   BioMuta; RNF125; -.
DR   DMDM; 143811449; -.
DR   PaxDb; Q96EQ8; -.
DR   PeptideAtlas; Q96EQ8; -.
DR   PRIDE; Q96EQ8; -.
DR   Ensembl; ENST00000217740; ENSP00000217740; ENSG00000101695.
DR   GeneID; 54941; -.
DR   KEGG; hsa:54941; -.
DR   UCSC; uc002kxf.2; human.
DR   CTD; 54941; -.
DR   DisGeNET; 54941; -.
DR   GeneCards; RNF125; -.
DR   H-InvDB; HIX0014384; -.
DR   HGNC; HGNC:21150; RNF125.
DR   HPA; HPA041514; -.
DR   MalaCards; RNF125; -.
DR   MIM; 610432; gene.
DR   MIM; 616260; phenotype.
DR   neXtProt; NX_Q96EQ8; -.
DR   OpenTargets; ENSG00000101695; -.
DR   PharmGKB; PA134950383; -.
DR   eggNOG; ENOG410IJHI; Eukaryota.
DR   eggNOG; ENOG410YBNH; LUCA.
DR   GeneTree; ENSGT00530000063064; -.
DR   HOGENOM; HOG000230946; -.
DR   HOVERGEN; HBG098958; -.
DR   InParanoid; Q96EQ8; -.
DR   KO; K12170; -.
DR   OMA; VTSFDCS; -.
DR   OrthoDB; EOG091G0LBM; -.
DR   PhylomeDB; Q96EQ8; -.
DR   TreeFam; TF331012; -.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   UniPathway; UPA00143; -.
DR   GeneWiki; RNF125; -.
DR   GenomeRNAi; 54941; -.
DR   PRO; PR:Q96EQ8; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000101695; -.
DR   CleanEx; HS_RNF125; -.
DR   ExpressionAtlas; Q96EQ8; baseline and differential.
DR   Genevisible; Q96EQ8; HS.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0034098; C:VCP-NPL4-UFD1 AAA ATPase complex; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0039536; P:negative regulation of RIG-I signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR008598; Di19_Zn_binding_dom.
DR   InterPro; IPR034734; ZF_C2HC_RNF.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF05605; zf-Di19; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51803; ZF_C2HC_RNF; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Complete proteome; Disease mutation;
KW   Golgi apparatus; Immunity; Lipoprotein; Membrane; Mental retardation;
KW   Metal-binding; Myristate; Reference proteome; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:17990982}.
FT   CHAIN         2    232       E3 ubiquitin-protein ligase RNF125.
FT                                /FTId=PRO_0000056090.
FT   ZN_FING      37     76       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     100    119       C2HC RNF-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01144,
FT                                ECO:0000303|PubMed:17990982}.
FT   REGION       43     45       Interaction with the C2HC RNF-type zinc
FT                                finger. {ECO:0000269|PubMed:27411375}.
FT   REGION      109    113       Interaction with the RING-type zinc
FT                                finger. {ECO:0000269|PubMed:27411375}.
FT   REGION      120    128       Linker region.
FT                                {ECO:0000269|PubMed:27411375}.
FT   REGION      210    224       Required for interaction with ubiquitin
FT                                and for autoubiquitination.
FT                                {ECO:0000269|PubMed:17990982}.
FT   METAL        37     37       Zinc 1. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        40     40       Zinc 1. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        52     52       Zinc 2. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        54     54       Zinc 2. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        57     57       Zinc 1. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        60     60       Zinc 1. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        72     72       Zinc 2. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL        75     75       Zinc 2. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL       100    100       Zinc 3. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL       103    103       Zinc 3. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL       115    115       Zinc 3. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   METAL       119    119       Zinc 3. {ECO:0000244|PDB:5DKA,
FT                                ECO:0000269|PubMed:27411375}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:17990982}.
FT   VARIANT     112    112       M -> I (in TNORS; dbSNP:rs786201014).
FT                                {ECO:0000269|PubMed:25196541}.
FT                                /FTId=VAR_073353.
FT   VARIANT     163    163       S -> L (in TNORS; dbSNP:rs373764886).
FT                                {ECO:0000269|PubMed:25196541}.
FT                                /FTId=VAR_073354.
FT   VARIANT     174    174       R -> C (in TNORS; dbSNP:rs370242930).
FT                                {ECO:0000269|PubMed:25196541}.
FT                                /FTId=VAR_073355.
FT   MUTAGEN       2      2       G->A: Abolishes ability to regulate T-
FT                                cell activation but not E3 ligase
FT                                activity in vitro. Also abolishes
FT                                myristoylation and membrane localization.
FT                                {ECO:0000269|PubMed:15843525,
FT                                ECO:0000269|PubMed:17643463,
FT                                ECO:0000269|PubMed:17990982}.
FT   MUTAGEN      37     37       C->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-40.
FT                                {ECO:0000269|PubMed:15843525,
FT                                ECO:0000269|PubMed:17643463,
FT                                ECO:0000269|PubMed:17990982}.
FT   MUTAGEN      40     40       C->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-37.
FT                                {ECO:0000269|PubMed:15843525,
FT                                ECO:0000269|PubMed:17990982}.
FT   MUTAGEN      54     54       H->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-57.
FT                                {ECO:0000269|PubMed:15843525}.
FT   MUTAGEN      57     57       C->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-54.
FT                                {ECO:0000269|PubMed:15843525}.
FT   MUTAGEN      72     72       C->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-75.
FT                                {ECO:0000269|PubMed:15843525,
FT                                ECO:0000269|PubMed:17460044,
FT                                ECO:0000269|PubMed:25591766}.
FT   MUTAGEN      75     75       C->A: Abolishes ability to regulate T-
FT                                cell activation and E3 ligase activity in
FT                                vitro; when associated with A-72.
FT                                {ECO:0000269|PubMed:15843525,
FT                                ECO:0000269|PubMed:17460044,
FT                                ECO:0000269|PubMed:25591766}.
FT   MUTAGEN     100    103       CAEC->AAEA: Abolished E3 ubiquitin-
FT                                protein ligase activity in vitro.
FT                                {ECO:0000269|PubMed:27411375}.
FT   MUTAGEN     109    113       LSEMR->ASEAA: Abolished E3 ubiquitin-
FT                                protein ligase activity in vitro.
FT                                {ECO:0000269|PubMed:27411375}.
FT   MUTAGEN     217    217       V->P: Reduced ubiquitination and reduced
FT                                binding to ubiquitinated proteins; when
FT                                associated with Q-221.
FT                                {ECO:0000269|PubMed:17990982}.
FT   MUTAGEN     221    221       S->Q: Reduced ubiquitination and reduced
FT                                binding to ubiquitinated proteins; when
FT                                associated with P-217.
FT                                {ECO:0000269|PubMed:17990982}.
FT   CONFLICT    105    108       TLVC -> IVLY (in Ref. 2; AAH12021).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       S -> N (in Ref. 1; BAA91182).
FT                                {ECO:0000305}.
FT   CONFLICT    232    232       T -> A (in Ref. 2; AAH12021).
FT                                {ECO:0000305}.
FT   TURN         38     40       {ECO:0000244|PDB:5DKA}.
FT   STRAND       45     49       {ECO:0000244|PDB:5DKA}.
FT   STRAND       55     57       {ECO:0000244|PDB:5DKA}.
FT   HELIX        58     67       {ECO:0000244|PDB:5DKA}.
FT   TURN         73     75       {ECO:0000244|PDB:5DKA}.
FT   STRAND       80     82       {ECO:0000244|PDB:5DKA}.
FT   HELIX        87     93       {ECO:0000244|PDB:5DKA}.
FT   STRAND       97     99       {ECO:0000244|PDB:5DKA}.
FT   TURN        101    103       {ECO:0000244|PDB:5DKA}.
FT   STRAND      106    108       {ECO:0000244|PDB:5DKA}.
FT   HELIX       109    111       {ECO:0000244|PDB:5DKA}.
FT   HELIX       112    118       {ECO:0000244|PDB:5DKA}.
FT   HELIX       120    126       {ECO:0000244|PDB:5DKA}.
SQ   SEQUENCE   232 AA;  26454 MW;  E3D93D546AD99D81 CRC64;
     MGSVLSTDSG KSAPASATAR ALERRRDPEL PVTSFDCAVC LEVLHQPVRT RCGHVFCRSC
     IATSLKNNKW TCPYCRAYLP SEGVPATDVA KRMKSEYKNC AECDTLVCLS EMRAHIRTCQ
     KYIDKYGPLQ ELEETAARCV CPFCQRELYE DSLLDHCITH HRSERRPVFC PLCRLIPDEN
     PSSFSGSLIR HLQVSHTLFY DDFIDFNIIE EALIRRVLDR SLLEYVNHSN TT
//
